BBOT — BridgeBio Oncology Therapeutics, Inc.
Price · 2024-08-26 → 2026-08-21
499 daily closes shownAnonymous view is capped at two years of history. A free account extends it to five, and Pro opens the whole archive back to 2024-02-09.
Performance
Technicals
Others in Healthcare
Measured signals that fired on BBOT
| date | signal | measured base rate |
|---|---|---|
| 2026-08-10 | Equal highs taken out structure | -0.70% over 21 days · t = -8.28 · n = 68,636 statistically distinguishable from its control group |
| 2026-06-18 | Volume shock without a price move price | -1.33% over 21 days · t = -4.53 · n = 16,432 statistically distinguishable from its control group |
| 2026-05-15 | Institutional holders jumped in a quarter ownership | -0.52% over 21 days · t = -0.38 · n = 1,553 not distinguishable from its control group |
| 2026-04-30 | Equal lows taken out structure | -0.64% over 21 days · t = -4.75 · n = 55,661 statistically distinguishable from its control group |
Excess return against a matched control group, on a point-in-time universe that includes delisted companies. Most families do not survive that. How the measurement works →
Insider transactions (Form 4)
| date | insider | what | shares | price | value |
|---|---|---|---|---|---|
| 2026-07-01 | Ben Yong Chief Med & Dev Officer | Shares withheld for tax | 1.0K | 7.80 | 8.2K |
| 2026-07-01 | Beltran Pedro President and CEO | Shares withheld for tax | 1.0K | 7.80 | 8.2K |
| 2026-07-01 | Elmelech Idan COO & Principal Financial Ofcr | Shares withheld for tax | 343 | 7.80 | 2.7K |
| 2026-07-01 | Cobo Marc Principal Accounting Officer | Shares withheld for tax | 125 | 7.80 | 975 |
| 2026-07-01 | Chen Bihua Director | Other Acquisition/Disposition | 2.7M | 0.00 | 0 |
| 2026-07-01 | Chen Bihua Director | Other Acquisition/Disposition | 1.7M | 0.00 | 0 |
| 2026-07-01 | Chen Bihua Director | Other Acquisition/Disposition | 4.5M | 0.00 | 0 |
| 2026-07-01 | Chen Bihua Director | Other Acquisition/Disposition | 130.9K | 0.00 | 0 |
| 2026-04-01 | Ben Yong Chief Med & Dev Officer | Shares withheld for tax | 1.0K | 9.03 | 9.5K |
| 2026-04-01 | Beltran Pedro President and CEO | Shares withheld for tax | 1.0K | 9.03 | 9.5K |
Open-market purchases (code P) are the informative ones. Grants, option exercises and tax withholding are compensation mechanics, not decisions. How to read a Form 4 →
Largest institutional holders
| manager | value | shares |
|---|---|---|
| Cormorant Asset Management, LP | 160.0M | 17.9M |
| DEERFIELD MANAGEMENT COMPANY, L.P. | 43.7M | 4.9M |
| Omega Fund Management, LLC | 29.4M | 3.3M |
| EcoR1 Capital, LLC | 25.3M | 2.8M |
| Alphabet Inc. | 25.3M | 2.8M |
| WELLINGTON MANAGEMENT GROUP LLP | 25.2M | 2.8M |
| ENAVATE SCIENCES GP, LLC | 23.5M | 2.6M |
| CITADEL ADVISORS LLC | 22.6M | 2.5M |
| NOVO HOLDINGS A/S | 19.6M | 2.2M |
| BlackRock, Inc. | 18.7M | 2.1M |
13F positions as of 2026-03-31, filed up to 45 days after quarter end. Long-only US equity — shorts and derivatives never appear. What 13F does and does not show →
Short selling
This is off-exchange short volume, not short interest: it is flow, not position, and 40–50% is normal because market makers short to fill your buy. Why that number misleads →
Recent headlines
- Bridgebio Oncology Therapeutics, Inc. (BBOT) filed form 8-K · 2026-08-11 · SEC EDGAR
Ask the AI about BBOT
The assistant reads every block on this page — price history, filings, insider transactions, institutional positions, short volume, macro and the measured base rates — and says what it implies, quoting the number behind each claim and declaring what it does not have.
Everything on this page is live in the terminal.
Charts, filings, insider flow and the AI — open without an account.
Free plan for good. Pro is $69.99/mo, or $4.99 for a 7-day trial. See the plans →